Thank you for your interest, we’ll get in touch with you shortly!
Sensorem is a Stockholm based tech start up that enables seniors to age safely and independently in their private homes by creating “Smart homes” (IoT) applied and customized for seniors.
The first product launched on the market is a stylish smart watch for seniors. When an accident occurs, relatives receive notifications and gets called up by the watch. Sensorem has the potential to make a real difference for millions of seniors!
Diabetes Services is building a human-centric digital ecosystem of data using services for diabetes- and lifestyle management for better health and quality of life.
There is a strong demand for imaging of retinal structures on a cellular level, such as photoreceptors and capillaries, in order to improve diagnosis of retinal disease and prevent vision loss. Profundus offers 10 times higher resolution than conventional retinal imaging instruments and 50 times higher corrected imaging area than competing concepts. Profundus aim to provide researchers and clinicians with a tool that can visualize currently subclinical changes of retinal disease.
Our aim is to offer clinicians and researchers one device that can perform multiple rapid neuro-ophthalmic eye examination tests. Our unique BulbiHUB platform and BulbiCAM currently offers the user multiple tests to screen for glaucoma, age-related macular degeneration (AMD) , nystagmus, cataract and optic neuritis. Ultimately our BulbiCAM will include multiple tests to screen for both ophthalmological and neurological conditions.
The primary challenge with neurodegenerative diseases and psychiatric disorders is that existing biomarkers are neither objective, detailed, nor cannot be easily reproduced. NeuraMetrix’s goal is to enable dramatically better care of patients with these diseases and disorders by providing physicians and researchers with an exceptionally precise and accurate biomarker measurement of brain health. For more information see https://www.neurametrix.com/neurametrix-tc/our-solution
We provide national approved e-ID for safe online, customer service and in app identifications. For large healthcare providers, we provide EU required identification for organizations domain and API client certificate, the QWAC, just like the open banking requirement. That is where the safe exchange of information between national healthcare providers, boarder controls and remote patient journeys starts. We protect users and corporations from phishing!
A game changing all-in-one solution, to analyze, eliminate and control snoring. Our mission is to help people around the globe who snore and have related health problems as snoring affect your health and heart, by launching a game-changing, preventive solution, which will help people stay healthy longer.
GlobePatient is a journal system (EHR / EMR) which provides an overview of the whole patient medical history, and works even off the cloud. World population is aging, and patients tend to have multimorbidities, for ex, diabetes, osteoporosis, cardiac problems, depression, each being treated by a doctor in a silo. Our solution patient centered, a ”helicopter view” over the most relevant information of the medical history, a report which can be customized and shared whenever needed.
Audientes’ mission is to make quality hearing solutions accessible and affordable to everyone who needs them. In other words, to help hearing-impaired people hear and interact freely. We will achieve this by designing, developing and bringing to market innovative solutions for the millions who simply cannot afford a traditional hearing aid or do not have access to an audiologist or hearing center.
Brain+ is a pioneer in developing Digital Therapeutics (DTx) products for treating and detecting Alzheimer’s and dementia. Digital Therapeutics are clinically validated, regulated and reimbursed medical products, on par with traditional drug treatments, only delivered digitally.
Currently, 1 in 3 seniors die with/of dementia in the US and globally 50 million people are diagnosed with dementia. This figure is expected to more than triple to 152 million people by 2050.